SOHO State of the Art Updates and Next Questions: Treatment Evolution of Mantle Cell Lymphoma: Navigating the Different Entities and Biological Heterogeneity of Mantle Cell Lymphoma in 2024
Clin Lymphoma Myeloma Leuk. 2024 Feb 22:S2152-2650(24)00082-X. doi: 10.1016/j.clml.2024.02.010. Online ahead of print.ABSTRACTProgress in mantle cell lymphoma (MCL) has led to significant improvement in outcomes of patients even in the real world (RW) setting albeit to a lesser degree. In parallel to the demonstration of benefit using combination therapy with rituximab plus high-dose cytarabine (R-AraC) as well as dose intensive therapy-autologous stem cell transplantation (DIT-ASCT) consolidation and maintenance, it became clear over the last 2 decades that MCL is a highly heterogenous disease at the molecular level, expl...
Source: Clinical Lymphoma and Myeloma - March 16, 2024 Category: Cancer & Oncology Authors: Andrew Ip Alexandra Della Pia Andre H Goy Source Type: research

PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma
CONCLUSION: Melflufen PVC and CVC administrations are bioequivalent based on melphalan pharmacokinetic parameters. Melflufen via PVC was well tolerated, with no infusion-related reactions or new safety signals and may represent an alternative route of administration.PMID:38490927 | DOI:10.1016/j.clml.2024.02.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 15, 2024 Category: Cancer & Oncology Authors: Ludek Pour Ilina Micheva Ganna Usenko Gabor Mikala Tamas Masszi Kameliya Simeonova Marcus Thuresson Gunilla Huledal Stefan Norin Nicolaas A Bakker Jiri Minarik Source Type: research

PORT: A Randomized, Cross-Over, Phase 2 Study of Melflufen Peripheral Versus Central Intravenous Administration in Patients With Relapsed/Refractory Multiple Myeloma
CONCLUSION: Melflufen PVC and CVC administrations are bioequivalent based on melphalan pharmacokinetic parameters. Melflufen via PVC was well tolerated, with no infusion-related reactions or new safety signals and may represent an alternative route of administration.PMID:38490927 | DOI:10.1016/j.clml.2024.02.012 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 15, 2024 Category: Cancer & Oncology Authors: Ludek Pour Ilina Micheva Ganna Usenko Gabor Mikala Tamas Masszi Kameliya Simeonova Marcus Thuresson Gunilla Huledal Stefan Norin Nicolaas A Bakker Jiri Minarik Source Type: research

SOHO State of the Art Updates and Next Questions, Measurable Residual Disease in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Clin Lymphoma Myeloma Leuk. 2024 Feb 21:S2152-2650(24)00081-8. doi: 10.1016/j.clml.2024.02.009. Online ahead of print.ABSTRACTAssessment of measurable residual disease (MRD) provides important prognostic information and can inform decision-making about appropriate consolidative therapy in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Many contemporary treatment protocols for Ph+ ALL achieve high rates of MRD negativity, and several analyses suggest that allogeneic hematopoietic stem cell transplant in first remission can be safely deferred in most patients who achieve MRD negativity...
Source: Clinical Lymphoma and Myeloma - March 14, 2024 Category: Cancer & Oncology Authors: Nicholas J Short Elias Jabbour Hagop Kantarjian Source Type: research

Alternative Dosing Schedules of Azacitidine: A Real-World Study Across South American Centers
Clin Lymphoma Myeloma Leuk. 2024 Feb 14:S2152-2650(24)00062-4. doi: 10.1016/j.clml.2024.02.003. Online ahead of print.NO ABSTRACTPMID:38462425 | DOI:10.1016/j.clml.2024.02.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 10, 2024 Category: Cancer & Oncology Authors: Lucas Castelo Wellington Fernandes da Silva Marco Lincango Valeria Buccheri Agustina Perusini Jorge Arbelbide Marcelo Iastrebner Jacqueline Gonzalez Patricio Pereyra Thales Dalessandro M Pereira Luan Lima Marchi Vanderson Rocha Carolina B Belli Elvira Deo Source Type: research

Alternative Dosing Schedules of Azacitidine: A Real-World Study Across South American Centers
Clin Lymphoma Myeloma Leuk. 2024 Feb 14:S2152-2650(24)00062-4. doi: 10.1016/j.clml.2024.02.003. Online ahead of print.NO ABSTRACTPMID:38462425 | DOI:10.1016/j.clml.2024.02.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 10, 2024 Category: Cancer & Oncology Authors: Lucas Castelo Wellington Fernandes da Silva Marco Lincango Valeria Buccheri Agustina Perusini Jorge Arbelbide Marcelo Iastrebner Jacqueline Gonzalez Patricio Pereyra Thales Dalessandro M Pereira Luan Lima Marchi Vanderson Rocha Carolina B Belli Elvira Deo Source Type: research

Alternative Dosing Schedules of Azacitidine: A Real-World Study Across South American Centers
Clin Lymphoma Myeloma Leuk. 2024 Feb 14:S2152-2650(24)00062-4. doi: 10.1016/j.clml.2024.02.003. Online ahead of print.NO ABSTRACTPMID:38462425 | DOI:10.1016/j.clml.2024.02.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 10, 2024 Category: Cancer & Oncology Authors: Lucas Castelo Wellington Fernandes da Silva Marco Lincango Valeria Buccheri Agustina Perusini Jorge Arbelbide Marcelo Iastrebner Jacqueline Gonzalez Patricio Pereyra Thales Dalessandro M Pereira Luan Lima Marchi Vanderson Rocha Carolina B Belli Elvira Deo Source Type: research

Alternative Dosing Schedules of Azacitidine: A Real-World Study Across South American Centers
Clin Lymphoma Myeloma Leuk. 2024 Feb 14:S2152-2650(24)00062-4. doi: 10.1016/j.clml.2024.02.003. Online ahead of print.NO ABSTRACTPMID:38462425 | DOI:10.1016/j.clml.2024.02.003 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 10, 2024 Category: Cancer & Oncology Authors: Lucas Castelo Wellington Fernandes da Silva Marco Lincango Valeria Buccheri Agustina Perusini Jorge Arbelbide Marcelo Iastrebner Jacqueline Gonzalez Patricio Pereyra Thales Dalessandro M Pereira Luan Lima Marchi Vanderson Rocha Carolina B Belli Elvira Deo Source Type: research

Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study
CONCLUSION: Nilotinib, dasatinib and flumatinib had comparable efficacy, and significantly higher therapy responses and higher FFS rates than imatinib in newly diagnosed CML patients. However, there were no significant differences in PFS and OS among these 4 TKIs. These real-world data may provide additional evidence for routine clinical assessments to identify more appropriate therapies.PMID:38461040 | DOI:10.1016/j.clml.2024.02.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 9, 2024 Category: Cancer & Oncology Authors: Xiaoshuai Zhang Na Xu Yunfan Yang Hai Lin Bingcheng Liu Xin Du Xiaoli Liu Rong Liang Chunyan Chen Jian Huang Huanling Zhu Ling Pan Xiaodong Wang Guohui Li Zhuogang Liu Yanqing Zhang Zhenfang Liu Jianda Hu Chunshui Liu Fei Li Wei Yang Li Meng Yanqiu Han Li Source Type: research

Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study
CONCLUSION: Nilotinib, dasatinib and flumatinib had comparable efficacy, and significantly higher therapy responses and higher FFS rates than imatinib in newly diagnosed CML patients. However, there were no significant differences in PFS and OS among these 4 TKIs. These real-world data may provide additional evidence for routine clinical assessments to identify more appropriate therapies.PMID:38461040 | DOI:10.1016/j.clml.2024.02.008 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 9, 2024 Category: Cancer & Oncology Authors: Xiaoshuai Zhang Na Xu Yunfan Yang Hai Lin Bingcheng Liu Xin Du Xiaoli Liu Rong Liang Chunyan Chen Jian Huang Huanling Zhu Ling Pan Xiaodong Wang Guohui Li Zhuogang Liu Yanqing Zhang Zhenfang Liu Jianda Hu Chunshui Liu Fei Li Wei Yang Li Meng Yanqiu Han Li Source Type: research

Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study
CONCLUSIONS: EMN23 showed that the burden of AL amyloidosis is substantial, highlighting the need for early disease diagnosis and effective treatments targeting the underlying pathology.PMID:38453615 | DOI:10.1016/j.clml.2024.01.013 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 7, 2024 Category: Cancer & Oncology Authors: Arnaud Jaccard Frank Bridoux Wilfried Roeloffzen Monique C Minnema Rui Bergantim Roman H ájek Cristina Jo ão M Teresa Cibeira Giovanni Palladini Stefan Sch önland Giampaolo Merlini Paolo Milani Meletios A Dimopoulos Sriram Ravichandran Ute Hegenbart He Source Type: research

Healthcare Resource Utilization and Cost-of-Illness in Systemic Light Chain (AL) Amyloidosis in Europe: Results From the Real-World, Retrospective EMN23 Study
CONCLUSIONS: EMN23 showed that the burden of AL amyloidosis is substantial, highlighting the need for early disease diagnosis and effective treatments targeting the underlying pathology.PMID:38453615 | DOI:10.1016/j.clml.2024.01.013 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 7, 2024 Category: Cancer & Oncology Authors: Arnaud Jaccard Frank Bridoux Wilfried Roeloffzen Monique C Minnema Rui Bergantim Roman H ájek Cristina Jo ão M Teresa Cibeira Giovanni Palladini Stefan Sch önland Giampaolo Merlini Paolo Milani Meletios A Dimopoulos Sriram Ravichandran Ute Hegenbart He Source Type: research

Epcoritamab, a promising therapy for Richter syndrome?
Clin Adv Hematol Oncol. 2024 Mar;22(2):90-91.NO ABSTRACTPMID:38446476 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 6, 2024 Category: Cancer & Oncology Authors: Arnon Kater Source Type: research

Epcoritamab, a promising therapy for Richter syndrome?
Clin Adv Hematol Oncol. 2024 Mar;22(2):90-91.NO ABSTRACTPMID:38446476 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 6, 2024 Category: Cancer & Oncology Authors: Arnon Kater Source Type: research

MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis
CONCLUSION: Our findings indicated that MUC20 regulated by eccDNA alleviates PI resistance of MM by modulating cuproptosis, which would provide novel strategies for the treatment of PI-resistant MM.PMID:38439082 | PMC:PMC10913264 | DOI:10.1186/s13046-024-02972-6 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 4, 2024 Category: Cancer & Oncology Authors: Xiaobin Wang Yingqing Shi Hua Shi Xiaoyu Liu Aijun Liao Zhuogang Liu Robert Z Orlowski Rui Zhang Huihan Wang Source Type: research